As of January 23, 2025, Intensity Therapeutics (INTS) has a market cap of $38.517 million USD. According to our data, Intensity Therapeutics is ranked No.8295 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $38.52 M |
44.89%
|
Dec 31, 2024 | $26.58 M |
-79.46%
|
Dec 29, 2023 | $0.13 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
MacroGenics
MGNX
|
$0.19 B |
-0.000 M
|
USA
|
Inovio Pharmaceuticals
INO
|
$81.23 M |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Gritstone bio
GRTS
|
$3.80 M |
2.350 M
|
USA
|
Arvinas
ARVN
|
$1.25 B |
0.000 M
|
USA
|
Market Cap | = | INTS Stock Price | * | INTS Shares Outstanding |
= | $2.55 | * | 15.10 M | |
= | $38.52 M |